starting dupilumab or biologics for eczema: what to expect
Biologic treatments like Dupilumab (dupilumab) sit at a different level of eczema treatment entirely - they're not something a GP prescribes as a first step, and most patient-facing information about them online is either clinician-focused continuing education or manufacturer marketing. There's a real gap in plain, lived-experience information about what actually starting one involves.
Where biologics fit in the treatment pathway
According to PCDS clinical guidance (the Primary Care Dermatology Society's Adult Eczema Primary Care Treatment Pathway), biologics sit outside the standard primary care treatment ladder entirely - they're a specialist, secondary-care decision, reached only once standard treatment (emollients plus appropriately used topical steroids, and often other systemic options) hasn't adequately controlled a case of eczema. This matters because it explains why biologics aren't something you can request from a GP directly - reaching one typically means a dermatology referral (see "NHS dermatology waiting times: what to do while you wait" - https://ayreczema.co.uk/#/articles/nhs-dermatology-waiting-times-what-to-do-while-you-wait) and a course of standard treatment first (see "the truth about steroid phobia" - https://ayreczema.co.uk/#/articles/steroid-phobia-our-peer-groups-real-views - if that standard treatment is the part you're hesitant about).
What people actually report once they start
Ayr's peer sessions, drawing on members currently on treatment, found a genuinely mixed picture rather than a single "it worked" or "it didn't" story:
Reduced efficacy over the treatment cycle was a theme some members reported, particularly noticing symptoms creeping back in the days approaching their next scheduled dose.
Ocular side effects - eye irritation or redness - came up as a real and sometimes significant issue for some, serious enough in at least one case to need an ophthalmology referral. This is a recognised side effect category with biologics like dupilumab, not an unusual one-off.
Some members reported being stable and satisfied on treatment, with meaningfully improved symptoms and no significant side effect burden.
"Nobody told me eye issues were even a possible side effect until I already had one. I wish someone had just said upfront: this might happen, here's what to watch for, here's when to flag it."
What's worth asking before you start
What's the realistic timeline for effect? Biologics aren't instant - ask your dermatologist what improvement, and by when, should count as "working."
What are the known side effects, including less commonly discussed ones like eye irritation, and what's the threshold for flagging something to your dermatology team versus waiting it out?
What happens as you approach the next dose? If reduced efficacy near the end of a dosing cycle is common, ask whether that's expected or whether your dosing interval might need reviewing.
What's the referral pathway if something needs specialist input, like an eye symptom needing ophthalmology - knowing this in advance saves time if it comes up.
The honest takeaway
Biologics represent a genuine option for eczema that hasn't responded to standard treatment, and for some people the difference is substantial. But "starting a biologic" is not a single predictable experience - efficacy, side effects, and how it interacts with your specific case all vary, and going in with realistic expectations (including the possibility of side effects that aren't widely discussed) makes the process considerably less disorientating.
This article reflects the shared, anonymised experience of members of the ayr Eczema Circle peer support group, alongside publicly available primary care guidance - it is not personalised medical advice. Any decision about starting or continuing a biologic treatment should be made with your dermatology team.
References
Primary Care Dermatology Society (PCDS), "Eczema - Adult - Primary Care Treatment Pathway" - https://www.pcds.org.uk/files/general/Adult_Eczema_Pathway-web.pdf
2. NICE, Technology Appraisal guidance database - https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance
Related reading
The truth about steroid phobia - https://ayreczema.co.uk/#/articles/steroid-phobia-our-peer-groups-real-views
NHS dermatology waiting times: what to do while you wait - https://ayreczema.co.uk/#/articles/nhs-dermatology-waiting-times-what-to-do-while-you-wait
Everything on this page is shared experience from our peer community, not medical advice. For clinical questions, please speak to your GP, dermatologist or NHS 111.